Syndax axatilimab misses primary endpoint in Phase 2 IPF trial, drops further development in indication
Bitget2026/10/12 20:01- Syndax reported topline results from its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis.
- The study missed its primary goal, leading Syndax to drop further development of axatilimab in idiopathic pulmonary fibrosis.
- Safety looked comparable to placebo, with no new safety signals flagged.
- Ongoing axatilimab trials in chronic graft-versus-host disease remain on track, with additional results expected later this year and in early 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan's Q3 adjusted revenue of $50.9 billions misses expectations, fixed income trading revenue unexpectedly drops 4%, US stocks fall over 2% pre-market | Financial Report Insights
JPMorgan's Q3 adjusted revenue amounted to $50.91 billions, falling short of the market expectation of $51.37 billions. Fixed income trading revenue declined by 4% year-on-year, marking its first drop in over two years, while equity trading revenue rose by 49% year-on-year to $4.95 billions, registering the best third-quarter performance on record. Net interest income exceeded expectations, but expenses were higher than anticipated. The bank also posted a net investment securities loss of $658 million.
Johnson & Johnson (JNJ.US) Q3 profit exceeds expectations and raises full-year guidance! Innovative pharmaceutical business grows, while device business still needs improvement
Johnson & Johnson reported better-than-expected results for the third quarter of 2026 and raised its full-year 2026 revenue and earnings guidance.
Crypto prices
More
